Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006-10-20
Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer.
Abstract
Purpose
Surgical resection is standard therapy in stage I non-small-cell lung cancer (NSCLC); however, many patients are inoperable due to comorbid diseases. Building on a previously reported phase I trial, we carried out a prospective phase II trial using stereotactic body radiation therapy (SBRT) in this population.
Patients and methods
Eligible patients included clinically staged T1 or T2 (< or = 7 cm), N0, M0, biopsy-confirmed NSCLC. All patients had comorbid medical problems that precluded lobectomy. SBRT treatment dose was 60 to 66 Gy total in three fractions during 1 to 2 weeks.
Results
All 70 patients enrolled completed therapy as planned and median follow-up was 17.5 months. The 3-month major response rate was 60%. Kaplan-Meier local control at 2 years was 95%. Altogether, 28 patients have died as a result of cancer (n = 5), treatment (n = 6), or comorbid illnesses (n = 17). Median overall survival was 32.6 months and 2-year overall survival was 54.7%. Grade 3 to 5 toxicity occurred in a total of 14 patients. Among patients experiencing toxicity, the median time to observation was 10.5 months. Patients treated for tumors in the peripheral lung had 2-year freedom from severe toxicity of 83% compared with only 54% for patients with central tumors.
Conclusion
High rates of local control are achieved with this SBRT regimen in medically inoperable patients with stage I NSCLC. Both local recurrence and toxicity occur late after this treatment. This regimen should not be used for patients with tumors near the central airways due to excessive toxicity.
Related Questions
What is the clinical significance of R50 in lung SBRT?
Small lesions are the hardest to plan and meet the constraints like the R50%. You are right that those parameters have not been associated with symptomatic pneumonitis. The only reliable predictor in retrospective studies has been increased PTV size. The R50, conformality index, and dose spillage va...
How do you approach lung tumors with vessel encasement, especially in someone with active hemoptysis?
It's a good question and not one that has a ton of published data to support. If you look at the GYN literature for palliation of vaginal bleeding, hypofractioned RT can be a very useful treatment, suggesting a role in other sites. My impression is always that those are very vascular malignanies and...
Should lung SBRT fractions be delivered on consecutive days, every other day, or perhaps an even more prolonged schedule?
For North Ameridcan Radiaton Oncologists whose experience with lung SBRT began when they participated in one or both of the RTOG lung SBRT protocols (0236, 0813), they would have quickly learned that their patients would be classified as having either "peripheral" or "central" tumors based on the de...
How were decisions made about what dose constraints to use in the recent RTOG protocols for lung SBRT?
This is a question that is frequently and appropriately asked by SBRT beginners and experienced practitioners. The history of SBRT in that regard replicates much of the historic experience in RT which is that the data generated from treating the patients generated the constraints, so to speak, as op...
Is there really substantial evidence to avoid central lesions for SBRT?
Much has been learned since the cautionary data from Indiana University was published showing increased toxicity when using SBRT for centrally-located lung cancers. One should be aware that there is an increased risk when treating tumors in this location with SBRT fractionation schemes. I am aware o...